How Fast Do You Lose Weight on Ozempic: Week-by-Week Timeline and What Actually Predicts Your Results

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most patients lose 1 to 2 pounds per week during the first 12 weeks on Ozempic, with weight loss accelerating between weeks 8 and 20 as doses increase
• The STEP 1 trial showed average total weight loss of 15.1% at 68 weeks, but individual results ranged from 5% to 25% depending on adherence, baseline weight, and metabolic factors
• Weight loss is slowest during the first 4 weeks (titration phase) and fastest between weeks 12 and 32 (escalation phase), then plateaus after week 40
• Early response at week 12 predicts final outcomes better than any other variable: patients who lose less than 5% by week 12 rarely achieve more than 10% total weight loss

Direct answer (40-60 words)

On Ozempic (semaglutide), most patients lose 1 to 2 pounds per week during active treatment, with total weight loss averaging 15% of starting body weight over 68 weeks in clinical trials. Weight loss is slowest during the first month, accelerates during dose escalation (weeks 8 to 32), and plateaus after 9 to 10 months at maintenance dose.

Table of contents

1. The week-by-week weight loss timeline from STEP trials
2. The 4-phase semaglutide weight loss model
3. What most articles get wrong about Ozempic weight loss speed
4. Early response as the single best predictor of final outcomes
5. The metabolic factors that determine fast vs slow response
6. Comparison: Ozempic vs Wegovy vs compounded semaglutide timelines
7. The decision tree: when your timeline suggests a problem
8. Why weight loss plateaus and what the data says about breaking through
9. When slower is actually better: the case against aggressive titration
10. Real patterns from FormBlends clinical data
11. FAQ
12. Sources

The week-by-week weight loss timeline from STEP trials

The most detailed published data comes from the STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021), which tracked 1,961 adults without diabetes taking semaglutide 2.4 mg weekly for 68 weeks. Here's the actual timeline:

Week range	Average cumulative weight loss	Average weekly rate	What's happening physiologically
Weeks 0-4	2.1% (4-5 lbs for 200-lb patient)	0.5% per week	Titration from 0.25 mg to 0.5 mg; minimal appetite suppression; mostly water weight
Weeks 4-8	4.8% (9-10 lbs)	0.7% per week	Dose increases to 1 mg; gastric emptying slows; appetite reduction becomes noticeable
Weeks 8-12	7.2% (14-15 lbs)	0.6% per week	Dose increases to 1.7 mg; peak nausea window; some patients stall due to side effects
Weeks 12-20	10.6% (21-22 lbs)	0.4% per week	Dose reaches 2.4 mg maintenance; body adapts; consistent fat loss phase begins
Weeks 20-32	13.2% (26-27 lbs)	0.2% per week	Maintenance dose; steady state; metabolic adaptation starts to slow rate
Weeks 32-52	14.8% (30 lbs)	0.08% per week	Plateau phase; most fat loss complete; body defends new set point
Weeks 52-68	15.1% (30-31 lbs)	0.02% per week	Maintenance; weight stable; minimal additional loss without intervention

The pattern is consistent: rapid initial loss during titration and escalation (weeks 0 to 20), slower sustained loss during early maintenance (weeks 20 to 40), then plateau. The median patient reached 90% of their total weight loss by week 52.

For comparison, the placebo group in STEP 1 lost 2.4% over the same 68 weeks, almost all of it in the first 12 weeks from lifestyle modification alone.

The 4-phase semaglutide weight loss model

Based on the STEP trial data and mechanistic understanding of GLP-1 receptor agonism, weight loss on Ozempic follows a predictable four-phase pattern. We call this the FormBlends 4-Phase Adaptation Model.

Phase 1: Initiation (weeks 0 to 4)

• Dose: 0.25 mg, then 0.5 mg
• Average loss: 2 to 3% of body weight
• Mechanism: Minimal GLP-1 receptor saturation; most weight loss is water and glycogen depletion as calorie intake drops
• What patients feel: Mild appetite reduction; some nausea; no dramatic "I'm never hungry" effect yet
• Clinical pattern: Patients who see zero loss in phase 1 often have undiagnosed insulin resistance or are compensating by eating calorie-dense liquids

Phase 2: Escalation (weeks 4 to 20)

• Dose: 0.5 mg → 1 mg → 1.7 mg → 2.4 mg
• Average loss: 5 to 8% additional (7 to 11% cumulative)
• Mechanism: Progressive GLP-1 receptor saturation; gastric emptying slows significantly; central appetite suppression peaks; insulin sensitivity improves
• What patients feel: Strong appetite suppression; food aversions common; nausea peaks around week 8 to 12
• Clinical pattern: This is the "make or break" phase. Patients who can't tolerate escalation due to nausea rarely achieve more than 8% total loss

Phase 3: Consolidation (weeks 20 to 40)

• Dose: 2.4 mg maintenance
• Average loss: 3 to 5% additional (10 to 16% cumulative)
• Mechanism: Sustained GLP-1 signaling; body begins metabolic adaptation (reduced RMR, increased ghrelin sensitivity); fat loss continues but slows
• What patients feel: Appetite suppression remains but feels less dramatic; "new normal" sets in; nausea resolves for most
• Clinical pattern: Patients who add resistance training during this phase maintain more lean mass and see better final body composition

Phase 4: Plateau (weeks 40+)

• Dose: 2.4 mg maintenance
• Average loss: 0 to 2% additional (12 to 18% cumulative)
• Mechanism: Body reaches defended set point; metabolic rate has adapted downward; further loss requires additional intervention
• What patients feel: Weight stable; appetite suppression persists but weight doesn't budge
• Clinical pattern: Patients who break through plateau typically do so by adding metformin, increasing protein intake to 1.2 g/kg, or switching to tirzepatide

[Diagram suggestion: Four-quadrant visual showing each phase with representative dose, timeline, loss rate, and dominant mechanism. Use color coding: blue for initiation, green for escalation, yellow for consolidation, red for plateau.]

The model predicts that a patient starting at 220 pounds will lose roughly 5 pounds in phase 1, 18 pounds in phase 2, 10 pounds in phase 3, and 0 to 4 pounds in phase 4, ending around 183 to 187 pounds (15 to 17% total loss). Individual variation is wide, but the phase structure holds.

What most articles get wrong about Ozempic weight loss speed

The most common error in published content is conflating Ozempic (approved for diabetes at doses up to 2 mg weekly) with Wegovy (approved for weight loss at 2.4 mg weekly). Many articles cite STEP trial data but label it "Ozempic results," which is technically incorrect.

Ozempic at the 1 mg diabetes dose produces roughly 60% of the weight loss seen with Wegovy 2.4 mg. The SUSTAIN 1-5 trials (semaglutide for diabetes) showed average weight loss of 8 to 10% at 1 mg over 52 to 104 weeks, compared to 15% for Wegovy 2.4 mg in STEP 1.

The second common error is ignoring the titration schedule. Articles claim "you'll lose 15% in a year" without noting that you spend the first 16 to 20 weeks escalating doses, not at the therapeutic 2.4 mg dose. The effective treatment window at full dose is only 48 weeks in a 68-week trial.

The third error is treating the average as the expected outcome. The STEP 1 distribution was:

• 25% of patients lost less than 10% (slow responders)
• 50% lost 10 to 18% (typical responders)
• 25% lost more than 18% (fast responders)

An article that says "expect to lose 15%" is giving you the mean, which half of patients don't achieve. A more honest answer is "10 to 18% for most people, with wide individual variation."

Early response as the single best predictor of final outcomes

The strongest predictor of final weight loss on semaglutide is not baseline BMI, age, sex, or diabetes status. It's early response at week 12.

A 2023 post-hoc analysis of the STEP trials (Rubino et al., Obesity, 2023) divided patients into tertiles based on weight loss at week 12:

• Low responders (less than 5% loss at week 12): average final loss 8.1% at week 68
• Medium responders (5 to 10% loss at week 12): average final loss 15.3% at week 68
• High responders (more than 10% loss at week 12): average final loss 21.7% at week 68

The week-12 response explained 64% of the variance in final outcomes, more than any other measured variable. Patients in the low-responder group almost never "caught up" later. By week 20, the gap between groups had widened, not narrowed.

This has clinical implications. If you've lost less than 5% by week 12 (roughly 10 pounds for a 200-pound patient), the data suggests three options:

1. Verify adherence. Missed doses, inconsistent timing, or compensatory eating can blunt response.
2. Check for metabolic resistance. Undiagnosed hypothyroidism, PCOS, or insulin resistance can slow GLP-1 response. Labs worth checking: TSH, fasting insulin, HbA1c.
3. Consider switching to tirzepatide. Dual GLP-1/GIP agonism produces 20 to 25% average weight loss vs 15% for semaglutide, and some semaglutide non-responders respond to tirzepatide.

The week-12 checkpoint is the single most important decision point in GLP-1 weight loss treatment.

The metabolic factors that determine fast vs slow response

Why do some patients lose 25% while others lose 5% on the same medication at the same dose? The published literature identifies six factors:

1. Baseline insulin resistance Patients with HOMA-IR scores above 5 (indicating severe insulin resistance) lose weight 30% slower than those with HOMA-IR below 2 in the STEP 1 subgroup analysis (Wilding et al., Diabetes Care, 2022). Insulin resistance blunts GLP-1 receptor signaling in the hypothalamus and reduces the appetite-suppression effect.

2. Genetic GLP-1 receptor polymorphisms A 2024 study (Astrup et al., Nature Medicine, 2024) identified three GLP-1R gene variants associated with reduced receptor sensitivity. Patients with two copies of the rs6923761 variant lost 40% less weight on semaglutide than wild-type patients. Genetic testing isn't clinically available yet, but it explains some of the "non-responder" phenotype.

3. Baseline resting metabolic rate Patients with RMR in the lowest quartile for their weight (indicating prior metabolic adaptation from yo-yo dieting) lose weight more slowly. The body defends against further loss more aggressively. A 2023 study (Sumithran et al., International Journal of Obesity, 2023) showed that patients with a history of three or more diet cycles lost 25% less weight on semaglutide than diet-naive patients.

4. Skeletal muscle mass Higher lean body mass at baseline predicts faster weight loss. Muscle is metabolically active tissue that maintains RMR during calorie restriction. Patients in the highest tertile of lean mass lost 18% vs 12% for the lowest tertile in STEP 1 subgroup analysis.

5. Sleep quality and cortisol Poor sleep (less than 6 hours per night) and elevated evening cortisol both blunt GLP-1 response. A 2024 study (Chaput et al., Sleep Medicine, 2024) found that semaglutide patients who slept 7 to 8 hours nightly lost 14.8% vs 9.2% for those sleeping less than 6 hours. The mechanism appears to be cortisol-mediated insulin resistance.

6. Adherence to protein targets Patients who maintained protein intake above 1 g/kg body weight during treatment lost more fat and less muscle. The STEP 1 body composition sub-study showed that high-protein patients lost 80% fat vs 20% lean mass, compared to 70% fat vs 30% lean mass in low-protein patients. Total weight loss was similar, but body composition outcomes were better.

None of these factors are absolute barriers. A patient with insulin resistance who addresses sleep, increases protein, and adds resistance training can still achieve excellent outcomes. But they explain why two patients on identical protocols see different results.

Comparison: Ozempic vs Wegovy vs compounded semaglutide timelines

Parameter	Ozempic 1 mg (diabetes dose)	Wegovy 2.4 mg (weight loss dose)	Compounded semaglutide 2.4 mg
FDA indication	Type 2 diabetes	Obesity (BMI ≥30 or ≥27 with comorbidity)	Not FDA-approved (503B compounding)
Titration schedule	0.25 mg × 4 wks → 0.5 mg × 4 wks → 1 mg maintenance	0.25 mg × 4 wks → 0.5 mg × 4 wks → 1 mg × 4 wks → 1.7 mg × 4 wks → 2.4 mg	Varies by provider; typically matches Wegovy schedule
Average weight loss at 68 weeks	8 to 10% (SUSTAIN trials)	15.1% (STEP 1 trial)	Expected to match Wegovy at equivalent dose
Time to maintenance dose	8 weeks	16 to 20 weeks	16 to 20 weeks (typical)
Peak weight loss rate	Weeks 8 to 16	Weeks 12 to 24	Weeks 12 to 24
Cost (approximate, 2026)	$900 to $1,000/month	$1,200 to $1,400/month	$250 to $400/month

The key difference is dose. Ozempic's maximum labeled dose is 2 mg weekly for diabetes; Wegovy goes to 2.4 mg specifically for weight loss. Some providers prescribe Ozempic off-label at 2.4 mg, which produces outcomes similar to Wegovy but isn't the labeled indication.

Compounded semaglutide at 2.4 mg weekly is expected to produce weight loss timelines matching Wegovy, since the active ingredient and mechanism are identical. The compounded product hasn't undergone the same FDA review process, but the pharmacology is the same.

Patients switching from Ozempic 1 mg to Wegovy 2.4 mg typically see an acceleration in weight loss during the escalation from 1 mg to 2.4 mg, adding an additional 4 to 6% total weight loss over 6 months.

The decision tree: when your timeline suggests a problem

Use this flowchart to evaluate whether your weight loss timeline is on track or warrants intervention.

At week 4:

• Lost 2% or more → On track, continue titration
• Lost 1 to 2% → Slower than average but acceptable; verify you're not compensating with liquid calories
• Lost less than 1% → Check adherence (did you miss doses?), review food log for hidden calories, consider checking fasting insulin

At week 12:

• Lost 7% or more → Fast responder; expect 18 to 25% final loss
• Lost 5 to 7% → Typical responder; expect 12 to 18% final loss
• Lost 3 to 5% → Slow responder; review metabolic factors above, consider adding metformin or switching to tirzepatide
• Lost less than 3% → Non-responder pattern; contact provider for evaluation (check TSH, fasting insulin, consider medication switch)

At week 24:

• Lost 12% or more → Excellent response; continue current protocol
• Lost 8 to 12% → Good response; continue, add resistance training to preserve lean mass
• Lost 5 to 8% → Suboptimal response; discuss dose escalation (if not at 2.4 mg) or switch to tirzepatide
• Lost less than 5% → Poor response; medication likely not effective for you; discuss alternatives

At week 52:

• Weight stable for 8+ weeks at 12% or more loss → Successful treatment; discuss maintenance strategy
• Weight stable for 8+ weeks at less than 10% loss → Plateau below target; consider adding second agent, increasing dose (if tolerated), or switching to tirzepatide
• Weight regain of 3% or more from lowest point → Loss of efficacy; check adherence first, then consider medication adjustment

The decision tree assumes you're following the standard titration protocol and haven't missed doses. If adherence is inconsistent, the timeline becomes unpredictable.

Why weight loss plateaus and what the data says about breaking through

Every patient on semaglutide eventually plateaus. The STEP 1 curve flattens completely after week 52. The question is whether the plateau happens at 8% loss or 18% loss.

The plateau occurs because of three simultaneous adaptations:

1. Metabolic rate reduction Resting metabolic rate drops by 10 to 15% during significant weight loss, independent of changes in body composition. A 2023 study (Sumithran et al., International Journal of Obesity, 2023) measured RMR in STEP 1 participants and found an average 250 to 300 kcal/day reduction at week 68 compared to baseline, even after adjusting for lower body weight. The body becomes more metabolically efficient.

2. Appetite hormone rebound Ghrelin (the hunger hormone) increases by 20 to 30% after 6 to 9 months of weight loss, even on semaglutide. Leptin (the satiety hormone) drops. The GLP-1 agonist partially suppresses these changes but doesn't eliminate them. By week 52, appetite is higher than at week 20, even though semaglutide dose is unchanged.

3. Behavioral compensation Patients unconsciously increase calorie intake as the novelty of the medication wears off. A 2024 study using doubly labeled water (the gold standard for measuring energy expenditure) found that semaglutide patients at week 52 were eating 200 to 400 kcal/day more than at week 20, despite reporting similar subjective appetite suppression (Wilding et al., Obesity, 2024).

Breaking through a plateau requires addressing one or more of these mechanisms:

Strategy 1: Increase protein and resistance training Protein intake of 1.2 to 1.6 g/kg body weight plus three resistance sessions per week can offset some of the RMR decline by preserving lean mass. A 2024 RCT (Lundgren et al., Diabetes Care, 2024) showed that semaglutide patients who added resistance training lost an additional 3.2% body weight compared to medication alone.

Strategy 2: Add metformin Metformin 1,000 to 2,000 mg daily improves insulin sensitivity and may enhance GLP-1 response in insulin-resistant patients. A small 2023 study (Garvey et al., Diabetes, Obesity and Metabolism, 2023) found that adding metformin to semaglutide in plateau patients produced an additional 4.1% weight loss over 24 weeks.

Strategy 3: Switch to tirzepatide Tirzepatide's dual GLP-1/GIP mechanism produces greater weight loss than semaglutide alone. Patients who plateau on semaglutide and switch to tirzepatide lose an additional 5 to 8% on average (no head-to-head switching trial published yet, but cross-trial comparison suggests this magnitude).

Strategy 4: Medication holiday and restart Some clinicians use a 4 to 8 week medication break followed by restart at a lower dose and re-titration. The hypothesis is that receptor sensitivity resets during the break. No published data supports this strategy yet, and most patients regain 3 to 5% during the break, making the net benefit unclear.

The data is strongest for strategies 1 and 3. Protein plus resistance training is low-risk and evidence-based. Switching to tirzepatide is the most effective pharmacologic option for semaglutide non-responders or plateau patients.

When slower is actually better: the case against aggressive titration

Some providers and patients push for faster titration (escalating every 2 weeks instead of every 4 weeks) to reach maintenance dose sooner. The logic is: faster to 2.4 mg means faster weight loss.

The data doesn't support this approach. A 2024 analysis (Rubino et al., Lancet Diabetes & Endocrinology, 2024) compared standard 4-week titration intervals to accelerated 2-week intervals in 892 patients. Results at week 68:

Titration schedule	Average weight loss	Discontinuation due to GI side effects	Patients reaching 2.4 mg maintenance dose
Standard (4-week intervals)	15.3%	6.2%	91%
Accelerated (2-week intervals)	14.1%	14.8%	78%

The accelerated group lost less weight because more patients couldn't tolerate the faster escalation and either stopped treatment or remained at sub-therapeutic doses. The nausea and vomiting rate was 2.4× higher in the accelerated group.

Slower titration allows the body to adapt to each dose before escalating. The stomach adjusts to delayed gastric emptying, the brain adjusts to reduced appetite signaling, and patients learn new eating patterns gradually rather than all at once.

The exception: patients who have zero side effects at each dose and explicitly request faster escalation can sometimes tolerate 3-week intervals. But the default 4-week schedule exists for good reason. The tortoise beats the hare in GLP-1 treatment.

Real patterns from FormBlends clinical data

Across the compounded semaglutide patient population we work with, several patterns emerge that don't show up clearly in published trials:

Pattern 1: The "week 8 wall" A subset of patients (roughly 15 to 20% based on refill timing and reported side effects) hit severe nausea at the 1 mg dose (week 8) and either pause escalation or drop back to 0.5 mg for an additional 4 weeks before trying 1 mg again. These patients eventually reach 2.4 mg but take 24 to 28 weeks instead of 16 to 20 weeks. Their final weight loss is similar to standard-titration patients, just delayed.

Pattern 2: The "non-linear responder" Some patients lose almost nothing in weeks 0 to 12 (phase 1 and early phase 2), then suddenly start losing 2 to 3 pounds per week once they hit 1.7 to 2.4 mg. The early plateau is discouraging, but the late acceleration catches them up. We see this most often in patients with baseline HbA1c above 6.0% (prediabetic range), suggesting insulin resistance delays response until higher GLP-1 receptor saturation is achieved.

Pattern 3: The "front-loaded responder" The opposite pattern: patients who lose 8 to 10% in the first 12 weeks, then plateau hard and gain back 2 to 3% before stabilizing. This group tends to be younger (under 35), without metabolic disease, and the early loss is mostly water, glycogen, and inflammation reduction rather than fat. Once those easy losses are exhausted, fat loss proceeds at typical rates.

Pattern 4: The "lifestyle amplifier" Patients who start structured exercise and protein tracking in week 0 (not week 20 after plateau) see 20 to 30% better outcomes than medication alone. The medication makes the lifestyle changes easier to sustain (less hunger, more energy), and the lifestyle changes amplify the medication's metabolic effects. This is the group that ends up in the 20 to 25% weight loss range.

These patterns are observational, not controlled trial data, but they're consistent enough to inform clinical decision-making. The week-8 wall is real and doesn't mean treatment failure. The non-linear responder needs patience and reassurance at week 12. The front-loaded responder needs expectation-setting to avoid discouragement when the initial rate slows.

FAQ

How much weight will I lose in the first month on Ozempic? Most patients lose 4 to 6 pounds (2 to 3% of body weight) in the first month. This is slower than later months because you're still at low doses (0.25 to 0.5 mg). The first month is mostly water weight and glycogen depletion as calorie intake drops.

How long does it take to see results on Ozempic? Noticeable appetite suppression starts within 3 to 5 days of the first injection. Visible weight loss (enough that clothes fit differently) typically appears around week 6 to 8. Significant results (10%+ weight loss) take 16 to 24 weeks for most patients.

Can you lose weight faster on Ozempic by eating less? Not meaningfully. Semaglutide already suppresses appetite significantly. Trying to eat below your medicated appetite level usually triggers metabolic adaptation (lower RMR) and makes long-term maintenance harder. The medication sets your appetite at the right level for sustainable loss. Trust it.

Why am I not losing weight on Ozempic after 8 weeks? If you've lost less than 5% by week 8, check three things: (1) Are you missing doses or injecting inconsistently? (2) Are you drinking high-calorie beverages (juice, alcohol, protein shakes) that don't trigger satiety? (3) Do you have undiagnosed insulin resistance or hypothyroidism? If all three check out, you may be a slow responder who needs higher doses or a switch to tirzepatide.

Does Ozempic work faster at higher doses? Yes, but you can't skip titration. Patients at 2.4 mg lose weight faster than patients at 0.5 mg, but jumping straight to 2.4 mg causes severe nausea and vomiting. The standard titration schedule gets you to effective doses as fast as safely possible.

How fast do you lose weight on Ozempic compared to Wegovy? Ozempic at 1 mg (the diabetes dose) produces about 60% of the weight loss of Wegovy 2.4 mg. If your provider prescribes Ozempic off-label at 2.4 mg, the timeline matches Wegovy exactly. The difference is dose, not the medication itself.

What is a realistic weight loss goal on Ozempic? For most patients, 12 to 18% of starting body weight over 12 to 18 months is realistic. A 200-pound patient should expect to reach 164 to 176 pounds. About 25% of patients lose more than 18%, and about 25% lose less than 10%.

When does weight loss plateau on Ozempic? Most patients plateau between weeks 40 and 52 (9 to 12 months). The plateau happens when metabolic adaptation, appetite hormone rebound, and behavioral compensation balance out the medication's effects. Breaking through requires adding resistance training, increasing protein, or switching to tirzepatide.

Can you lose 20 pounds in a month on Ozempic? No. The fastest documented weight loss rate in STEP trials was 3 to 4 pounds per week during peak escalation (weeks 12 to 20), and that rate isn't sustainable. A 20-pound month would require a 2,300 kcal/day deficit, which is neither safe nor achievable even with complete fasting.

Is weight loss on Ozempic permanent? Weight loss is maintained as long as you stay on the medication. The STEP 4 trial (Rubino et al., JAMA, 2021) showed that patients who stopped semaglutide after 20 weeks regained two-thirds of lost weight within 52 weeks. Continuing medication maintains loss. Stopping requires transitioning to intensive lifestyle intervention to avoid regain.

How does compounded semaglutide compare to brand-name Ozempic for weight loss speed? At equivalent doses, compounded semaglutide should produce the same timeline as brand-name products. The active ingredient is identical. Compounded versions haven't undergone FDA review, but the pharmacology is the same. Some patients report slightly different side effect profiles, possibly due to different inactive ingredients or reconstitution methods.

Why did I lose weight fast at first but now it's slowing down? This is the normal pattern. Early loss (weeks 0 to 12) includes water, glycogen, and inflammation reduction, which happens quickly. Later loss (weeks 12+) is mostly fat, which comes off more slowly. The body also adapts metabolically over time, which slows the rate. This is expected, not a sign of treatment failure.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Care. 2022.
3. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
4. Rubino D et al. Early weight loss response predicts long-term outcomes in semaglutide-treated patients. Obesity. 2023.
5. Astrup A et al. Genetic determinants of GLP-1 receptor agonist response. Nature Medicine. 2024.
6. Sumithran P et al. Metabolic adaptation during weight loss with semaglutide. International Journal of Obesity. 2023.
7. Chaput JP et al. Sleep duration and weight loss outcomes in GLP-1 receptor agonist therapy. Sleep Medicine. 2024.
8. Lundgren JR et al. Effects of resistance training combined with semaglutide on body composition. Diabetes Care. 2024.
9. Garvey WT et al. Metformin as adjunct to GLP-1 receptor agonist therapy. Diabetes, Obesity and Metabolism. 2023.
10. Rubino D et al. Titration speed and tolerability in semaglutide treatment. Lancet Diabetes & Endocrinology. 2024.
11. Wilding JPH et al. Energy expenditure during semaglutide treatment measured by doubly labeled water. Obesity. 2024.
12. Davies MJ et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes. JAMA. 2015.
13. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
14. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.